Inovio Pharmaceuticals (INO) Competitors

$1.46 +0.09 (+6.57%)

Closing price 05/8/2026 04:00 PM Eastern

Extended Trading

$1.65 +0.19 (+13.29%)

As of 05/8/2026 07:59 PM Eastern

INO vs. MRNA, CV, RXST, TLSI, and CARL

Should you be buying Inovio Pharmaceuticals stock or one of its competitors? The main competitors of Inovio Pharmaceuticals include Moderna (MRNA), CapsoVision (CV), RxSight (RXST), TriSalus Life Sciences (TLSI), and Carlsmed (CARL).

How does Inovio Pharmaceuticals compare to Moderna?

Inovio Pharmaceuticals (NASDAQ:INO) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Inovio Pharmaceuticals presently has a consensus target price of $6.75, indicating a potential upside of 362.33%. Moderna has a consensus target price of $35.73, indicating a potential downside of 34.25%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Inovio Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

Inovio Pharmaceuticals has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,689.71	-$84.95M	-$1.68	N/A
Moderna	$1.94B	11.09	-$2.82B	-$8.15	N/A

Inovio Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-259.70%	-83.46%
Moderna	-143.55%	-26.64%	-19.32%

Inovio Pharmaceuticals has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Moderna had 35 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 43 mentions for Moderna and 8 mentions for Inovio Pharmaceuticals. Moderna's average media sentiment score of 0.47 beat Inovio Pharmaceuticals' score of 0.37 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Moderna	17 Very Positive mention(s)	9 Positive mention(s)	4 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Inovio Pharmaceuticals beats Moderna on 9 of the 16 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to CapsoVision?

Inovio Pharmaceuticals (NASDAQ:INO) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Inovio Pharmaceuticals presently has a consensus target price of $6.75, indicating a potential upside of 362.33%. CapsoVision has a consensus target price of $8.50, indicating a potential upside of 19.38%. Given Inovio Pharmaceuticals' higher possible upside, equities research analysts plainly believe Inovio Pharmaceuticals is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

CapsoVision has higher revenue and earnings than Inovio Pharmaceuticals. CapsoVision is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,689.71	-$84.95M	-$1.68	N/A
CapsoVision	$13.55M	26.19	-$25.32M	-$2.19	N/A

CapsoVision's return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-259.70%	-83.46%
CapsoVision	N/A	N/A	N/A

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Inovio Pharmaceuticals had 7 more articles in the media than CapsoVision. MarketBeat recorded 8 mentions for Inovio Pharmaceuticals and 1 mentions for CapsoVision. Inovio Pharmaceuticals' average media sentiment score of 0.37 beat CapsoVision's score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
CapsoVision	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Inovio Pharmaceuticals beats CapsoVision on 9 of the 15 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to RxSight?

Inovio Pharmaceuticals (NASDAQ:INO) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by insiders. Comparatively, 9.6% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Inovio Pharmaceuticals presently has a consensus target price of $6.75, indicating a potential upside of 362.33%. RxSight has a consensus target price of $9.44, indicating a potential upside of 61.44%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Inovio Pharmaceuticals is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93

RxSight has higher revenue and earnings than Inovio Pharmaceuticals. RxSight is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,689.71	-$84.95M	-$1.68	N/A
RxSight	$134.48M	1.80	-$38.94M	-$0.95	N/A

Inovio Pharmaceuticals has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500. Comparatively, RxSight has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500.

Inovio Pharmaceuticals has a net margin of 0.00% compared to RxSight's net margin of -36.58%. RxSight's return on equity of -17.01% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-259.70%	-83.46%
RxSight	-36.58%	-17.01%	-15.12%

In the previous week, RxSight had 4 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 12 mentions for RxSight and 8 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 0.37 beat RxSight's score of -0.40 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
RxSight	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Inovio Pharmaceuticals and RxSight tied by winning 8 of the 16 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to TriSalus Life Sciences?

Inovio Pharmaceuticals (NASDAQ:INO) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Inovio Pharmaceuticals currently has a consensus target price of $6.75, suggesting a potential upside of 362.33%. TriSalus Life Sciences has a consensus target price of $7.00, suggesting a potential upside of 58.01%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Inovio Pharmaceuticals is more favorable than TriSalus Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

TriSalus Life Sciences has higher revenue and earnings than Inovio Pharmaceuticals. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,689.71	-$84.95M	-$1.68	N/A
TriSalus Life Sciences	$45.15M	6.02	-$39.23M	-$1.83	N/A

Inovio Pharmaceuticals has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.

Inovio Pharmaceuticals has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -86.88%. TriSalus Life Sciences' return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-259.70%	-83.46%
TriSalus Life Sciences	-86.88%	N/A	-94.43%

In the previous week, Inovio Pharmaceuticals had 5 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 8 mentions for Inovio Pharmaceuticals and 3 mentions for TriSalus Life Sciences. Inovio Pharmaceuticals' average media sentiment score of 0.37 beat TriSalus Life Sciences' score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
TriSalus Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Inovio Pharmaceuticals beats TriSalus Life Sciences on 12 of the 16 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Carlsmed?

Inovio Pharmaceuticals (NASDAQ:INO) and Carlsmed (NASDAQ:CARL) are both small-cap medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

In the previous week, Inovio Pharmaceuticals and Inovio Pharmaceuticals both had 8 articles in the media. Carlsmed's average media sentiment score of 0.48 beat Inovio Pharmaceuticals' score of 0.37 indicating that Carlsmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Carlsmed	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Inovio Pharmaceuticals has a net margin of 0.00% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-259.70%	-83.46%
Carlsmed	-57.76%	-60.74%	-29.84%

Inovio Pharmaceuticals currently has a consensus target price of $6.75, suggesting a potential upside of 362.33%. Carlsmed has a consensus target price of $19.33, suggesting a potential upside of 97.28%. Given Inovio Pharmaceuticals' higher probable upside, research analysts plainly believe Inovio Pharmaceuticals is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Carlsmed has higher revenue and earnings than Inovio Pharmaceuticals. Carlsmed is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,689.71	-$84.95M	-$1.68	N/A
Carlsmed	$50.51M	5.27	-$29.63M	-$2.51	N/A

Summary

Inovio Pharmaceuticals beats Carlsmed on 8 of the 14 factors compared between the two stocks.

Get Inovio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INO vs. The Competition

Export

Metric	Inovio Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$95.13M	$3.37B	$6.25B	$12.13B
Dividend Yield	N/A	2.25%	2.78%	5.20%
P/E Ratio	-0.87	15.36	20.68	25.39
Price / Sales	1,689.71	298.49	534.01	76.01
Price / Cash	N/A	124.38	43.29	53.47
Price / Book	4.06	7.32	9.99	6.83
Net Income	-$84.95M	$24.17M	$3.55B	$333.37M
7 Day Performance	32.73%	2.20%	3.50%	3.10%
1 Month Performance	39.05%	4.45%	4.16%	7.12%
1 Year Performance	-19.56%	78.68%	41.82%	41.28%

Inovio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INO Inovio Pharmaceuticals	2.243 of 5 stars	$1.46 +6.6%	$6.75 +362.3%	N/A	$95.13M	$60K	N/A	320	News Coverage Upcoming Earnings Analyst Downgrade Gap Up High Trading Volume
MRNA Moderna	1.1974 of 5 stars	$50.73 flat	$33.87 -33.2%	N/A	$20.04B	$1.94B	N/A	4,700	Trending News Earnings Report Options Volume Analyst Revision
CV CapsoVision	1.3652 of 5 stars	$6.07 flat	$8.50 +40.0%	N/A	$302.53M	$13.55M	N/A	90
RXST RxSight	2.3274 of 5 stars	$7.25 flat	$9.78 +34.9%	N/A	$299.21M	$134.48M	N/A	220	News Coverage Analyst Forecast
TLSI TriSalus Life Sciences	1.6523 of 5 stars	$4.64 flat	$7.00 +50.9%	N/A	$284.48M	$45.15M	N/A	106	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INO) was last updated on 5/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inovio Pharmaceuticals (INO) Competitors

INO vs. MRNA, CV, RXST, TLSI, and CARL

How does Inovio Pharmaceuticals compare to Moderna?

Summary

How does Inovio Pharmaceuticals compare to CapsoVision?

Summary

How does Inovio Pharmaceuticals compare to RxSight?

Summary

How does Inovio Pharmaceuticals compare to TriSalus Life Sciences?

Summary

How does Inovio Pharmaceuticals compare to Carlsmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INO vs. The Competition

Inovio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inovio Pharmaceuticals (INO) Competitors

INO vs. MRNA, CV, RXST, TLSI, and CARL

How does Inovio Pharmaceuticals compare to Moderna?

Do analysts rate INO or MRNA?

Which has preferable earnings and valuation, INO or MRNA?

Is INO or MRNA more profitable?

Which has more volatility and risk, INO or MRNA?

Do institutionals and insiders believe in INO or MRNA?

Does the media prefer INO or MRNA?

Summary

How does Inovio Pharmaceuticals compare to CapsoVision?

Do analysts rate INO or CV?

Which has preferable earnings and valuation, INO or CV?

Is INO or CV more profitable?

Do institutionals and insiders believe in INO or CV?

Does the media prefer INO or CV?

Summary

How does Inovio Pharmaceuticals compare to RxSight?

Do institutionals and insiders believe in INO or RXST?

Do analysts rate INO or RXST?

Which has preferable earnings and valuation, INO or RXST?

Which has more volatility and risk, INO or RXST?

Is INO or RXST more profitable?

Does the media prefer INO or RXST?

Summary

How does Inovio Pharmaceuticals compare to TriSalus Life Sciences?

Do insiders & institutionals believe in INO or TLSI?

Do analysts recommend INO or TLSI?

Which has higher earnings & valuation, INO or TLSI?

Which has more risk and volatility, INO or TLSI?

Is INO or TLSI more profitable?

Does the media favor INO or TLSI?

Summary

How does Inovio Pharmaceuticals compare to Carlsmed?

Does the media refer more to INO or CARL?

Do insiders & institutionals believe in INO or CARL?

Is INO or CARL more profitable?

Do analysts recommend INO or CARL?

Which has higher earnings & valuation, INO or CARL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INO vs. The Competition

Inovio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools